2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Systematic thyroid screening in myotonic dystrophy: link between thyroid volume and insulin resistance

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Myotonic dystrophy (DM1), a neuromuscular disease related to DMPK gene mutations, is associated to endocrine disorders and cancer. A routine endocrine work-up, including thyroid ultrasound (US), was conducted in 115 genetically-proven DM1 patients in a neuromuscular reference center. The aim of this study was to determine the prevalence and the causes of US thyroid abnormalities in DM1.

          Results

          In the whole population (age 45.1 ± 12.2 years, 61.7% female), palpable nodules or goiters were present in 29.2%. The percentage of US goiter (thyroid volume > 18 mL) and US nodules were, respectively, 38.3 and 60.9%. Sixteen of the 115 patients had a thyroidectomy, after 22 fine-needle aspiration cytology guided by thyroid imaging reporting and data system (TIRADS) classification. Six micro- (1/6 pT3) and 3 macro-papillary thyroid carcinoma (PTCs) (2/3 intermediate risk) were diagnosed (7.9% of 115). Thyroid US led to the diagnosis of 4 multifocal and 2 unifocal (including 1 macro-PTC) non-palpable PTCs. Ultrasound thyroid volume was positively correlated to body mass index (BMI) ( p = 0.015) and parity ( p = 0.036), and was inversely correlated to TSH ( p < 0.001) and vitamin D levels ( p = 0.023). The BMI, the frequencies of glucose intolerance and PTC were significantly higher in UsGoiter versus non-UsGoiter groups.

          Conclusion

          In this systematically screened DM1 cohort, the frequency of UsGoiter, mainly associated to BMI, was about 40%, US nodules 60%, thyroidectomies 13–14%, and PTCs 8%, two-thirds of them being micro-PTCs with good prognosis. Therefore, a systematic screening remains debatable. A targeted US screening in case of clinical abnormality or high BMI seems more appropriate.

          Electronic supplementary material

          The online version of this article (10.1186/s13023-019-1019-3) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features

          American Thyroid Association (ATA) leadership asked the ATA Thyroid Nodules and Differentiated Thyroid Cancer Guidelines Task Force to review, comment on, and make recommendations related to the suggested new classification of encapsulated follicular variant papillary thyroid carcinoma (eFVPTC) without capsular or vascular invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The task force consists of members from the 2015 guidelines task force with the recusal of three members who were authors on the paper under review. Four pathologists and one endocrinologist were added for this specific review. The manuscript proposing the new classification and related literature were assessed. It is recommended that the histopathologic nomenclature for eFVPTC without invasion be reclassified as a NIFTP, given the excellent prognosis of this neoplastic variant. This is a weak recommendation based on moderate-quality evidence. It is also noted that prospective studies are needed to validate the observed patient outcomes (and test performance in predicting thyroid cancer outcomes), as well as implications on patients' psychosocial health and economics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification.

            The broad clinical spectrum of myotonic dystrophy type 1 (DM1) creates particular challenges for both medical care and design of clinical trials. Clinical onset spans a continuum from birth to late adulthood, with symptoms that are highly variable in both severity and nature of the affected organ systems. In the literature, this complex phenotype is divided into three grades (mild, classic, and severe) and four or five main clinical categories (congenital, infantile/juvenile, adult-onset and late-onset forms), according to symptom severity and age of onset, respectively. However, these classifications are still under discussion with no consensus thus far. While some specific clinical features have been primarily reported in some forms of the disease, there are no clear distinctions. As a consequence, no modifications in the management of healthcare or the design of clinical studies have been proposed based on the clinical form of DM1. The present study has used the DM-Scope registry to assess, in a large cohort of DM1 patients, the robustness of a classification divided into five clinical forms. Our main aim was to describe the disease spectrum and investigate features of each clinical form. The five subtypes were compared by distribution of CTG expansion size, and the occurrence and onset of the main symptoms of DM1. Analyses validated the relevance of a five-grade model for DM1 classification. Patients were classified as: congenital (n=93, 4.5%); infantile (n=303, 14.8%); juvenile (n=628, 30.7%); adult (n=694, 34.0%); and late-onset (n=326, 15.9%). Our data show that the assumption of a continuum from congenital to the late-onset form is valid, and also highlights disease features specific to individual clinical forms of DM1 in terms of symptom occurrence and chronology throughout the disease course. These results support the use of the five-grade model for disease classification, and the distinct clinical profiles suggest that age of onset and clinical form may be key criteria in the design of clinical trials when considering DM1 health management and research.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis

                Bookmark

                Author and article information

                Contributors
                +33 (0)6 63007407 , +33 (0)3 2 0444 535 , adrien.benhamou@hotmail.fr
                stephanie.espiard@live.fr
                christine.docao@chru-lille.fr
                miriam.ladsous@chru-lille.fr
                cloyer88@gmail.com
                alexandre.moerman@chru-lille.fr
                samuel.boury@chru-lille.fr
                m.kyheng.chr@gmail.com
                claire-marie.dhaenens@inserm.fr
                v-tiffreau@chru-lille.fr
                pascal.pigny@chru-lille.fr
                gilles.lebuffe@chru-lille.fr
                robert.caiazzo@univ-lille2.fr
                sebastien.aubert@chru-lille.fr
                +33 (0)6 63007407 , +33 (0)3 2 0444 535 , mc-vantyghem@chru-lille.fr
                Journal
                Orphanet J Rare Dis
                Orphanet J Rare Dis
                Orphanet Journal of Rare Diseases
                BioMed Central (London )
                1750-1172
                13 February 2019
                13 February 2019
                2019
                : 14
                : 42
                Affiliations
                [1 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Endocrinology, Diabetology and Metabolism, ; F-59000 Lille, France
                [2 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Clinical Genetics, ; F-59000 Lille, France
                [3 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Radiology, ; F-59000 Lille, France
                [4 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, EA 2694 – Public Health, Epidemiology and Quality of Care, ; F-59000 Lille, France
                [5 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, Univ Lille, Inserm, CHU Lille, UMR 837-1, Alzheimer & Tauopathies, ; F-59000 Lille, France
                [6 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille Neuromuscular Reference Center, ; F-59000 Lille, France
                [7 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Institute of Biochemistry and Molecular Biology – Biology Center, ; F-59000 Lille, France
                [8 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Anesthesiology, ; F-59000 Lille, France
                [9 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, General and Endocrine Surgery, ; F-59000 Lille, France
                [10 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, CHU Lille, Institute of Biochemistry and Molecular Biology – Pathology Center, ; F-59000 Lille, France
                [11 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, Univ Lille, Inserm, CHU Lille, UMR 1190 Translational Research in Diabetes, ; F-59000 Lille, France
                [12 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, EGID European Genomics Institute for Diabetes, CHU Lille, ; F-59000 Lille, France
                [13 ]ISNI 0000 0004 0471 8845, GRID grid.410463.4, Department of Endocrinology, Diabetology and Metabolism, CHR-U Lille, ; 1, Rue Polonovski, 59037 Lille, France
                Author information
                http://orcid.org/0000-0002-4986-8658
                http://orcid.org/0000-0002-9369-0463
                Article
                1019
                10.1186/s13023-019-1019-3
                6375124
                30760283
                d8803df3-5f34-4c18-a7ac-49880bf18198
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 12 July 2018
                : 3 February 2019
                Categories
                Research
                Custom metadata
                © The Author(s) 2019

                Infectious disease & Microbiology
                myotonic dystrophy,papillary thyroid carcinoma,ultrasound scan,thyroid nodule,thyroid goiter

                Comments

                Comment on this article